| [February 15, 2012] |
 |
BIO Industry Analysis Investor Survey: FDA Approvals Expected to Increase and Majority of Investors Believe Now Is a Good Time to Invest in Biotech
WASHINGTON --(Business Wire)--
The 14th annual BIO CEO & Investor Conference wrapped up in
New York City yesterday amidst renewed optimism among investors and
signs that FDA approvals may be on the rise in 2012, according to BIO
Industry Analysis survey data. The event closed with a record number of
one-on-one meetings, increased attendance and panel sessions on the
latest investment and deal making trends. Hosted by the Biotechnology
Industry Organization (BIO), the event drew more than 1,200 industry
leaders and hosted more than 1,300 one-on-one meetings.
"The BIO CEO & Investor Conference synthesized the overall mood within
the industry of momentum and progress with recent approvals and
increased M&A activity, and optimism for the year ahead," said Alan
Eisenberg, executive vice president of Emerging Companies and Business
Development at BIO.
In 2012 alone, four new drugs have been approved by the FDA: Bydureon
for type 2 diabetes; Kalydeco for cystic fibrosis; Erivedge for basal
cell carcinoma and Inlyta for renal cell carcinoma, with two more
approved with companion diagnostics: Xalkori for NSCLC and Zelboraf for
metastatic melanoma.
The study also indicates a majority of investors (56%) still think now
is a good time to invest, specifically with early stage companies and
those focused on autoimmune disease and oncology. Furthermore, the data
indicates investors expect a marked increase in biotech IPO's in 2012.
The conference hosted three plenary sessions addressing the economic and
business issues facing the biotech industry. The event also hosted three
Business Roundtables and four Therapeutic Workshops. The Business
Roundtables focused on biotech drug launches, unique business models and
licensing and deal-making while the Therapeutic Workshops discussed
topics such as oncology, companion diagnostics and neurological and
cardiovascular diseases. Additionally, BIO introduced Fireside Chats to
this year's program which included a set of moderated, one-on-one
conversations with pharma R&D chiefs and industry leaders, followed by
an interactive question and answer session.
The BIO One-on-One Partnering system which provides the opportunity to
arrange meeings between investors, companies and industry executives
saw a record breaking 1,300 one-on-one meetings between 225 companies
and featured 140 company presentations.
The BIO CEO & Investor Conference is the largest independent investor
conference focused solely on publicly-traded biotechnology companies.
Investors attend to network with top biotechnology executives, evaluate
fresh investment opportunities, attend candid panel discussions and get
an overview of the industry and key issues affecting investments.
Upcoming BIO Events
BIO
IP Counsels Committee Conference
April 16-18, 2012
Austin,
TX
World
Congress on Industrial Biotechnology & Bioprocessing
April
29-May 2, 2012
Orlando, FL
2012
BIO International Convention
June 18-21, 2012
Boston, MA
BIO
Business Forum
June 18-21, 2012
Boston, MA
About BIO
BIO represents more than 1,100 biotechnology companies, academic
institutions, state biotechnology centers and related organizations
across the United States and in more than 30 other nations. BIO members
are involved in the research and development of innovative healthcare,
agricultural, industrial and environmental biotechnology products. BIO
also produces the BIO International Convention, the world's largest
gathering of the biotechnology industry, along with industry-leading
investor and partnering meetings held around the world. BIO produces BIOtechNOW, a
multiblog platform and monthly newsletter that aims to create an online
biotech community where the the industry can connect to discuss the
latest news. Subscribe
to BIOtechNOW.
For more information:
Visit http://www.bio.org
Follow
us on Twitter (News - Alert) @IAmBiotech
Join
us on LinkedIn/MyBio
Become
a fan at facebook.com/IAmBiotech
[ Back To TMCnet.com's Homepage ]
|
TMCnet LOGIN
Webinars
